What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Metastatic Breast Cancer
Proceedings from a live event on June 3, 2024, held during the ASCO 2024 Annual Meeting and moderated by Dr Hope S Rugo. Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo. Published June 28, 2024.
Topics:
• Introduction (0:00)
• Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) - Dr Hurvitz (4:38)
• Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC - Dr Burstein (30:11)
• Selection and Sequencing of Treatment for Patients with HR-Positive, HER2-Negative mBC Who Experience Disease Progression on CDK4/6 Inhibition - Dr Rugo (48:15)
• Current and Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease - Prof Curigliano (1:07:24)
• Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer - Dr O’Shaughnessy (1:22:11)
• Current and Future Strategies for the Care of Individuals with Endocrine-Refractory HR-Positive mBC - Dr Bardia (1:42:24)
The entire program, slides, CME information, and, select publications:
www.researchto...
2 окт 2024
